價(jià)格 | 詢(xún)價(jià) | ||
包裝 | 1支 | 1支 | 1支 |
最小起訂量 | 1支 |
發(fā)貨地 | 湖北 |
更新日期 | 2025-01-24 |
中文名稱(chēng):托萊西單抗 | 英文名稱(chēng):Research Grade Tafolecimab (DHJ24007) |
CAS:2225109-03-3 | 純度規(guī)格: PAGE:>95% |
產(chǎn)品類(lèi)別: 藥物對(duì)照抗體 | |
抗體名: Research Grade Tafolecimab (DHJ24007) | 靶點(diǎn): NARC1, PCSK9 |
宿主: Homo sapiens | 適應(yīng)物種: Human |
克隆性: Monoclonal | 藥物對(duì)照抗體: Research Grade Tafolecimab (DHJ24007) |
Catalog No.
DHJ24007
Host species
Homo sapiens
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG2-kappa
Applications
Research Grade Biosimilar
Target
Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
Q8NBP7
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
IBI-306, CAS: 2225109-03-3
Note
For research use only. Not suitable for clinical or therapeutic use.
成立日期 | 2021-04-08 (4年) | 注冊(cè)資本 | 700萬(wàn) |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1000萬(wàn)-5000萬(wàn) |
主營(yíng)行業(yè) | 生物化工,技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 試劑 |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢(xún)價(jià) |
VIP1年
|
湖南瑞威爾生物科技有限公司
|
2024-11-29 | |
¥15000 |
VIP5年
|
武漢維斯?fàn)柭锕こ逃邢薰?/div>
|
2025-01-20 | |
詢(xún)價(jià) |
VIP3年
|
江西瑞威爾生物科技有限公司
|
2025-01-14 |